# Rec'd PCT/PTO 01 AUG 2005

PCT/FR2003/003740



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

	nec u PC	MPIO OT AUG 2005
canslation internat	PATENT COOPERATION TRI	PCT/FR2003/
nslat	PCT	, reskes neife in veine im estus um iten (
INTERNAT	IONAL PRELIMINARY EXAMIN	ATION REPORT
	(PCT Article 36 and Rule 70)	
Applicant's or agent's file reference 02143PCT	FOR FURTHER ACTION See Notifi	ication of Transmittal of Internations Examination Report (Form PCT/IPEA/416
International application No. PCT/FR2003/003740	International filing date (day/month/year) 16 décembre 2003 (16.12.2003)	Priority date (day/month/year) 16 décembre 2002 (16.12.2002)
International Patent Classification (IPC) or a A61K 9/48	national classification and IPC	
Applicant	DADIG I	
	PARIS, Laurence	
This international preliminary exam     and is transmitted to the applicant act	ination report has been prepared by this International to Article 36.	ational Preliminary Examining Authority
2. This REPORT consists of a total of	5 sheets, including this cover sh	neet.
This report is also accompani amended and are the basis for	ed by ANNEXES, i.e., sheets of the description this report and/or sheets containing rectificating the PCT).	
These annexes consist of a tot	ander the FC1).	
3. This report contains indications relati	ing to the following items:	
I Basis of the report		
II Priority		
III Non-establishment of	opinion with regard to novelty, inventive step	and industrial applicability
IV Lack of unity of inver		
V Reasoned statement u citations and explanat	nder Article 35(2) with regard to novelty, inve ions supporting such statement	entive step or industrial applicability;
VI Certain documents cit		
VII Certain defects in the	international application	•
	on the international application	
ate of submission of the demand	Date of completion of the	his report —
09 juillet 2004 (09.07.20		arch 2005 (31.03.2005)
ame and mailing address of the IPEA/EP	Authorized officer	
esimile No.	Telephone No.	

Form PCT/IPEA/409 (cover sheet) (July 1998)




International application No.

PCT/FR2003/003740

s of the repo	t	
n regard to th	elements of the international application:*	
	-	
•		
• • —		, as originally filed
· • —		, filed with the demand
	, filed with the letter of	
		·
	1-16, 17 (part.), 24 (part.), 25-36	, as originally filed
· -	, as amended (togeth	er with any statement under Article 19
pages		filed with the demand
pages	17 (part.), 18-23, 24 (part.) , filed with the letter of	09 February 2005 (09.02.2005)
the drawing	:	
pages		
pages		, as originally filed
pages	filed with the law of	, filed with the demand
e sequence l	ting port of the death of	
		, as originally filed
Dages		filed with the days t
•	filed with the letter of	
the language or 55.3).  regard to an nary examination tailed together furnished substituting the statement on the language.	of publication of the international application (under Rule 48.3(b)).  of the translation furnished for the purposes of international preliminary  nucleotide and/or amino acid sequence disclosed in the internation was carried out on the basis of the sequence listing:  ne international application in written form.  with the international application in computer readable form.  equently to this Authority in written form.  that the subsequently furnished written sequence listing does not opplication as filed has been furnished.	examination (under Rule 55.2 and/ ional application, the international go beyond the disclosure in the
the description the draw	ription, pagesns, Nos	
	the internation the descript pages p	the international application as originally filed the description: pages

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT



V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
i	citations and explanations supporting such statement

Statement			
Novelty (N)	Claims	11, 17, 20, 25, 28, 29	YES
	Claims	1-10, 12-16, 18, 19, 21-23, 26, 27, 30-36	NO
Inventive step (IS)	Claims		YES
	Claims	1-36	NO
Industrial applicability (IA)	Claims	1-36	YES
	Claims		NO

#### Citations and explanations

This report makes reference to the following documents:

D1: US 2002/019447 A1

D2: FR-A-2 767 070, cited in the application

D3: WO 01/07507 A

In the absence of other indications, reference is made to the passages cited in the international search report.

Polysaccharide compositions (thickening agents) that can be used to produce hard and soft capsules, and that jellify after the admixture of complexing agents, are known from the prior art. D1, for example, describes filmforming compositions produced from hydrocolloidal sols (such as konjac/xanthan, guar/xanthan, etc.) with the admixture of boron salts; figure 6, in particular, shows the use of clarified hydrocolloids for producing various types of soft capsules. The mannans and gums used are thickening agents in that they produce viscous sols (cf. column 2, [0018] and [0020]).

D2 describes capsule skins produced from carrageen. On page 3, a list is found with the types of carrageens that can be used. Lambda carrageen is mentioned as a thickening

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

agent. In the examples, a mixture of carrageens appears to be used, hence including lambda carrageens. Moreover, the same additives are used as in the present application.

In D3, soft capsules are produced from pullulan with the optional admixture of polysaccharides, such as gum arabic, wellan, rhamsan. Additives that are similar or identical to those in the present application are added.

The plasticising, surfactant, disintegrant additives, etc. used in the present application are also conventional additives, and their composition depends on the type of product that is to be produced.

For these reasons, the subject matter of claims 1-10, 12-16, 18, 19, 21-23, 26, 27 and 30-36 does not appear to be novel over D1-D3 (PCT Article 33(1) and 33(2)).

### It should be noted that

- the use of xanthan gum (thickener), for example, is not excluded from the generic wording of claim 1;
- the presence of gelling agents is not excluded from claim 1;
- the mention of a different use (soft/hard capsules) cannot render compositions novel over prior art compositions containing the same ingredients.

An inventive step could be recognised for possibly novel aspects (restriction to certain thickeners, absence of gelling agents) of the application only if a surprising effect were demonstrated.